Skip to main content

Wellcome Trust Provides $9.4M to Make Galapagos Predictive Drug Data Public

NEW YORK (GenomeWeb News) – A grant and license agreement involving the UK’s Wellcome Trust, the Belgian company Galapagos, and the European Molecular Biology Laboratory's European Bioinformatics Institute will open up the rights to databases held by Galapagos division BioFocus DPI for use by public research communities.
 
EMBL-EBI will use a Wellcome Trust grant of £4.7 million ($9.4 million) to support the transfer of a collection of information on drug properties and a set of Galapagos’ drug-like small molecules to the Institute. EMBL-EBI will incorporate the data into its collection of open-access resources for use in biomedical research.
 
Galapagos will receive £1.4 million for the data, which it previously offered for license through its BioFocus DPI service division.
 
The Galapagos databases covered under the agreement are DrugStore, StARLITe, Strudle, Kinase SARfari, and GPCR SARfari.
 
The agreement does not include the StarDrop software platform, which BioFocus DPI will continue to offer.
 
"The scientific community worldwide will greatly benefit from the access to these data for aiding predictive drug discovery," Galapagos CEO Onno van de Stolpe said in a statement.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.